At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 246 enrolled
Drug / intervention
etanerceptbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Canadian Assessment of Patient Outcomes and Effectiveness of Enbrel (Etanercept) in Psoriasis
In Brief
A Phase 4 clinical trial evaluating etanercept for Psoriasis. Completed, enrolled 246 participants.
Detailed Summary
The purpose of this study is to evaluate the use of etanercept (Enbrel®) in the treatment of psoriasis in patients for a period of up to 1 year.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
Countries--
CollaboratorsWyeth is now a wholly owned subsidiary of Pfizer
Timeline
Phase 4CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2006
First PostedJun 2006
Primary CompletionJul 2009
Study CompletionFeb 2010
TodayJul 2026
First PostedJun 1, 2006
Enrollment StartMar 1, 2006
Primary CompletionJul 1, 2009
Study CompletionFeb 1, 2010
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 20.1 years ago
Interventions
etanerceptbiological
etanercept subcutaneous injection